-
Feb 20, 2024 | 
thepatientstory.com | Jenna Jones
February 20, 2024As you navigate your cancer journey, questions about diet often bubble to the surface. Dr. Urvi Shah, is a board-certified hematologist-oncologist at Memorial Sloan Kettering and a Hodkin lymphoma patient. Dr. Shah led a clinical trial studying the effects of a plant-based diet on cancer patients. She sheds light on the relationship between sugar, soda, and overall diet. In this interview, Dr. Shah provides insight into the effects of diet on cancer.
-
Jan 10, 2024 | 
thepatientstory.com | Jenna Jones
January 11, 2024In this discussion, we delve into the distinction between two types of blood cancer: leukemia and lymphoma. Confusion often arises because both are blood cancers. Leukemia typically occurs in the bone marrow, while lymphoma originates in the lymphatic system, primarily impacting lymph nodes and tissue.
-
Dec 20, 2023 | 
thepatientstory.com | Jenna Jones
December 20, 2023Receiving a chronic lymphocytic leukemia (CLL) diagnosis is likely to lead to a very human question: How long can I or my loved one live with CLL? To answer that question, we went directly to two CLL experts who have seen patients at all different stages.
-
Dec 14, 2023 | 
thepatientstory.com | Jenna Jones
December 15, 2023Accelerated approval was granted to Pirtobrutinib (JAYPIRCA, Eli Lilly and Company) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
-
Dec 12, 2023 | 
thepatientstory.com | Jenna Jones
December 12, 2023Patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) face a compromised immune system, heightening the risk of infections. Vaccinations are often recommended for people with CLL/SLL but patients may still have questions. To address CLL and vaccinations, we invited a CLL expert panel to discuss the question specifically.
-
Dec 12, 2023 | 
thepatientstory.com | Jenna Jones
Multiple myeloma patient outcomes are strikingly different in the real-world versus controlled environments according to data presented at the ASH Conference 2023 (Abstract 541). In the real world, multiple myeloma patients demonstrated a 44% reduction in progression-free survival (PFS) and a 75% decrease in overall survival (OS) compared to participants in clinical trials.
-
Dec 9, 2023 | 
thepatientstory.com | Jenna Jones
The headlines about the recent FDA investigation into CAR T-cell therapy have raised questions about the cancer treatment for many patients. To provide some answers, we sat down with Dr. Joshua Brody, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at Mount Sinai, at the ASH conference in San Diego 2023. As background, the FDA is investigating T-cell malignancies associated with BCMA- or CD19-directed autologous CAR T-cell immunotherapies.
-
Oct 25, 2023 | 
thepatientstory.com | Jenna Jones
Downloadable: CLL Global Patient Packet The Patient Story Downloadable: CLL Global Patient Packet
-
Sep 27, 2023 | 
thepatientstory.com | Jenna Jones
September 27, 2023Benefits and Considerations: Navigating Momelotinib’s Usage with Dr. MascarenhasIn a significant development, the US Food and Drug Administration (FDA) has granted approval to OJJAARA (momelotinib) for the treatment of intermediate or high-risk myelofibrosis (This includes cases of primary myelofibrosis and secondary myelofibrosis occurring after polycythemia vera and essential thrombocythemia) in adults with anemia, according to a media release by GSK.
-
Aug 15, 2023 | 
thepatientstory.com | Jenna Jones
August 15, 2023In a significant stride forward for the field of multiple myeloma treatment, the U.S. Food and Drug Administration (FDA) has recently granted accelerated approvals for two innovative therapies, elranatamab-bcmm (Elrexfio) and talquetamab-tgvs. These approvals mark critical advancements in addressing the complex challenges faced by adults with relapsed or refractory multiple myeloma, a condition characterized by resistance to previous therapies.
